Accelerated Approval May Support Smaller Trials In Acute Diseases – FDA
Executive Summary
Final guidance on expedited regulatory pathways suggests FDA is open to accelerated approval for some acute conditions; agency also provides examples outside of HIV/cancer arena where surrogate and intermediate clinical endpoints have supported approval.
You may also be interested in...
Accelerated Approval Should Be Less 'Wide Open,' Califf Says
FDA should write more about its interpretation of regs and apply it more consistently across divisions, commissioner says.
FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure
Letter being circulated by Rep. Bilirakis states the agency’s draft expedited approval guidance does not provide clarity for rare disease sponsors to use accelerated approval.
One Loss, One Tie: US FDA Panels Prove Difficult For Opioid Sponsors Intellipharmaceutics, Esteve
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: